Drugs With Tirzepatide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Zepbound and Mounjaro Eye Side Effect NAION Information Page provides some important evidence regarding an increased risk of non-arteritic ischemic optic neuropathy, or NAION, associated with these two tirzepatide-containing drugs.
The FDA has been investigating “potential signals” of the eye side effect NAION with Mounjaro and Zepbound — the active ingredient is tirzepatide for both medications — as well as other glucagon-like peptide-1 (GLP-1) receptor agonist drugs, collectively referred to as GLP-1 RAs. To learn more about how Zepbound and Mounjaro might be associated with the eye side effect NAION, you can read our June 2025 Drug Injury Watch blog post, “Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs”.
An August 2025 JAMA Network Open article, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“, provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic (semaglutide) or Mounjaro (tirzepatide) in diabetes patients.
Here are some of the facts presented in that August 2025 medical article regarding the Mounjaro eye side effect NAION, specifically in diabetes patients:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- The medical researchers compared Mounjaro (tirzepatide) with other antidiabetic medications for the associated risk of NAION in patients with type 2 diabetes who had no prior diagnosis of any eye disorder.
- Mounjaro (tirzepatide) is a newer and more potent GLP-RA to treat type 2 diabetes and obesity.
- In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that when Mounjaro (tirzepatide) was compared with other antidiabetic medications, there was an increased risk of NAION.
Besides Mounjaro, as we stated earlier, there is a second GLP-1RA drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes. There is some evidence that the NAION eye side effect may be associated with Zepbound, given that both drugs have the active ingredient tirzepatide.
Of course, we will continue to monitor relevant medical journals for additional studies concerning the association of NAION with Mounjaro and Zepbound. Further, we await the outcome of that FDA investigation into the eye side effect NAION with Mounjaro and Zepbound.
Free Case Evaluation for Zepbound or Mounjaro Eye Side Effect NAION
We encourage you to submit a Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Zepbound or Mounjaro drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Articles About Zepbound and Mounjaro Eye Side Effect NAION With Vision Loss
NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
The eye side effect non-arteritic anterior ischemic optic neuropathy (NAION) linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs is the focus of an April 2026 medical study report published online by JAMA Network Open.
This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy“, presents a 2025 analysis of 2017 – 2023 health records from the US Department of Veterans Affairs (VA) done to investigate the rate of this NAION eye side effect that users of Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have reported.
To read more of this article, click below:
When all was said and done, the authors of this 2026 medical study report about NAION concluded:
In this large cohort study, [Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs] use was associated with a modestly increased risk of NAION compared with [sodium-glucose cotransporter-2 inhibitors (SGLT2i) drugs] use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.
NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs is an issue that first came to light in the second part of 2024. For example, two large medical studies from Denmark found that people who used Ozempic had double the risk of developing NAION, which can cause vision loss and blindness.
In the past couple of years, NAION drug injury lawsuits involving Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have been filed against the responsible pharmaceutical companies for their failure to warn patients and doctors about the risk of developing NAION.
For an introduction to the medical and legal aspects of these NAION drug injury lawsuits, here are two relevant Drug Injury Law website links:
- Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
- Zepbound and Mounjaro Eye Side Effect NAION Information Page
We are investigating cases of NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs for patients as drug injury lawsuits seeking legal compensation for their vision loss. We point out that those NAION lawsuits would not be filed against the patients’ doctors because the pharmaceutical company failed to warn about the NAION eye side effect associated with their drug.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Mounjaro and Zepbound:
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound